Histological support for the difference between malignant hyperthermia susceptible (MHS), equivocal (MHE) and negative (MHN) muscle biopsies

British Journal of Anaesthesia

Volumn 79, Issue 3, 1997, Pages 327-331

  Mezin, P ^a   Payen, J F ^a   Bosson, J L ^a   Brambilla, E ^a   Stieglitz, P ^a  

^a HÔPITAL MICHALLON   (France)

Author keywords

Malignant, hyperthermia; Measurement techniques, histology

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; DISEASE PREDISPOSITION; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MALIGNANT HYPERTHERMIA; MUSCLE ATROPHY; MUSCLE BIOPSY; MUSCLE CONTRACTILITY; MUSCLE HYPERTROPHY; MUSCLE NECROSIS; PRIORITY JOURNAL;

EID: 0030850414     PISSN: 00070912     EISSN: None     Source Type: Journal    
DOI: 10.1093/bja/79.3.327     Document Type: Article

References (25)

1. Denborough MA, Lowel RRH. Anaesthetic deaths in a family. Lancet 1960; 1: 45.
2. Harriman DGF, Ellis FR, Franks AJ, Sumner DW. Malignant hyperthermia myopathy in man: an investigation of 75 families In: Aldrete JA, Britt BA, eds. Proceedings of the Second International Symposium on Malignant Hypenhermia. New York: Grune and Stratton, 1978; 67-87.
3. Isaacs H. Myopathy and malignant hyperthermia. In: Aldrete JA, Britt BA, eds. Proceedings of the Second International Symposium on Malignant Hyperthermia. New York: Grune and Stratton, 1978; 89-101.
4. Ellis FR, Halsall PJ, Ording H, Fletcher R, Rankley E, Heffron JA, Lehane M, Mortier W, Stinbereitner K, Sporn P, Theunynck D, Verburg R. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. British Journal of Anaesthesia 1984; 56: 1267-1269.
5. Vila A, Mezin P. Examens complémentaires en pathologie musculaire. Annales Francaises d'Anesthesie et de Reanimation 1989; 8: 406-410.
6. Mezin P, Tenaud C, Bosson JL, Stoebner P. Morphometric analysis of the peripheral nerve: advantages of the semi-automated interactive method. Journal of Neuroscience Methods 1994; 51: 163-169.
7. Figarella Branger D, Pellissier JF. Myopathie de l'hyperrhermie maligne. In: Aubert M, Borsarelli J, Kosak Ribbens G, eds Congrès "Hyperthermies Malignes" Marseille 1992. 1993; 31-43.
8. Krivosic I, Krivosic-Horber R, Adnet P, Dupont A. Correlation of histopathologic, histoenzymologic and histometric analysis with in vitro tests for MH in series of 42 adult cases. Beitrage zur Anaesthesie und Intensivmedizin 1989; 27: 223-230.
9. Ellis FR, Heffron JJA. Clinical and biochemical aspects of malignant hyperpyrexia. Recent Advances in Anaesthesia and Analgesia 1985; 15: 173-207.
10. Harriman DGF. The definition of normal muscle and of malignant hyperthermia myopathy, and the association of myopathies with the malignant hyperthermia trait. Muscle and Nerve 1986; (suppl. 1): 222.
11. Romero NB, Nivoche Y, Lunardi J, Bruneau B, Cheval MA, Hillaire D, Fardeau M. Malignant hyperthermia and central core disease: analysis of two families with heterogeneous clinical expression. Neuromuscular Disorders 1993; 3: 547-551.
12. Eng GD, Epstein BS, Engel WK, McKay DW, McKay R. Malignant hyperthermia and central core disease in a child with congenital dislocating hips. Archives of Neurology 1978; 35: 189-197.
13. Krivosic-Horber R, Adnet P, Krivosic I, Reyford H. Diagnostic de la sensibilité à l'hyperthermie maligne chez l'enfant. Archives Francaises de Pediatrie 1990; 47: 421-424.
14. Heiman-Patterson T, Martino C, Rosenberg H, Fletcher J, Tahmoush A. Malignant hyperthermia in myotonia congenita. Neurology 1988; 38: 810-812.
15. Isaacs H, Badenhorst ME, Du Sautoy C. Myophosphorylase B deficiency and malignant hyperthermia. Muscle and Nerve 1989; 12: 203-205.
16. Rieske-Nielsen E. Malignant hyperthermia in Denmark: survey of a family study and investigations into muscular morphology in ten additional cases. In: Aldrete JA, Britt BA, eds. Proceedings of the Second International Symposium on Malignant Hyperthermia. New York: Grune and Stratton, 1978 ; 287-327.
17. Stelzner J, Kretz FJ, Rieger A, Reinhart K. Anaesthetic-induced heart arrest. A case report of 2 infants with previously unrecognized muscular dystrophy. Anaesthesist 1993; 42: 44-46.
18. Deufel T, Muller-Felber W, Pongratz DE, Hubner G, Johnson K, Iaizzo PA, Lehmann-Horn F. Chronic myopathy in a patient suspected of carrying two malignant hyperthermia susceptibility (MHS) mutations. Neuromuscular Disorders 1992; 2: 389-396.
19. Heiman-Patterson TD, Rosenberg H, Fletcher JE, Tahmoush AJ. Halothane-caffeine contracture testing in neuromuscular diseases. Muscle and Nerve 1988; 11: 453-457.
20. Harriman DGF. Microscopy in malignant hyperthermia investigation. In: Britt BA, ed. Malignant Hyperthermia 1987; 295-308.
21. Harriman DGF. Malignant hyperthermia myopathy - a critical review. British Journal of Anaesthesia 1988; 60: 309-316.
22. Harnden-Mayor P, Franks AJ, Halsall PJ, Howell M, Ellis FR. Histomorphologic changes in malignant hyperpyrexia. Beitrage zur Anaesthesie und Intensivmedizin 1989; 27: 45-49.
23. Bergeson PS, Kaplan AM, Gregg SA, Curless RG. Malignant Hyperthermia associated with characteristic physical findings, myopathy and normal muscle enzymes: a syndrome. In: Aldrete JA, Britt BA, eds. Proceedings of the Second International Symposium on Malignant Hyperthermia. New York: Grune and Stratton 1978; 473-482.
24. Ellis FR. Malignant hyperthermia. In: Inherited Disease and Anaesthesia. Elsevier/North-Holland Biomedical Press, 1981; 163-211.
25. Stadhouders AM, Viering WAL, Sengers RCA. Histochemical aspects of malignant hyperthermia. Beitrage zur Anaesthesie und Intensivmedizin 1989; 27: 50-66.